Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
Date:7/30/2009

o received ANA773 at 1600 mg. Anadys expects to present further results from this study later this year and intends to explore partnership opportunities as a potential path to continue the development of ANA773.
  • Reported PK/PD Data for ANA773 in HCV at EASL. In April 2009, the pharmacokinetic (PK) and pharmacodynamic (PD) data from the healthy volunteer portion of the Phase I clinical trial of ANA773 in HCV were reported at the EASL conference. ANA773 was generally well tolerated with no serious adverse events. Plasma drug levels were proportional to dose, and there was a dose-dependent induction of well-recognized interferon dependent biomarkers.
  • Phase I Clinical Trial in Oncology. In order to focus its resources on ANA598, Anadys recently elected to stop enrollment of new patients in the ongoing Phase I oncology trial of ANA773. Anadys plans for currently enrolled patients to continue to receive ANA773 until disease progression is observed and to conclude the trial once all patients reach this point.
  • Webcast of Conference Call

    Anadys will host a conference call at 5:00 pm Eastern Daylight Time today to discuss its second quarter 2009 financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 85411914. The webcast and telephone replay will be available through August 13, 2009.

    About Anadys

    Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of
    '/>"/>

    SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    2. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    3. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    4. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    5. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    6. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    7. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
    8. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
    9. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
    10. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
    11. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... -- With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness of ... than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More ... Headquartered in Dallas, TX , ISN has additional offices ...
    (Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
    (Date:7/30/2015)... ... ... As part of its 2015 growth plan and as a follow up to the recently ... Whitehouse Laboratories is pleased to announce that it has begun construction on a new Microbiological ... will be strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific ...
    (Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
    Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
    ... , , , ... FOLD ) will announce second quarter 2009 financial results after the ... announcement will be followed by a live conference call and webcast ... Interested participants and investors may access the conference call at ...
    ... , ... Change at ... constant on a constant, ... 2009 basis rates H1 2009 basis rates, ...
    ... , ... in Cardiac Core Lab Industry , ... Rochester, NY (PRWEB) July 29, 2009 -- iCardiac Technologies, Inc., a leader in advanced ... of 45 million cardiac cycles for agency facing studies in a single month utilizing the ...
    Cached Biology Technology:Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date 2Sanofi-aventis Announces Second Quarter 2009 Results 2Sanofi-aventis Announces Second Quarter 2009 Results 3Sanofi-aventis Announces Second Quarter 2009 Results 4Sanofi-aventis Announces Second Quarter 2009 Results 5Sanofi-aventis Announces Second Quarter 2009 Results 6Sanofi-aventis Announces Second Quarter 2009 Results 7Sanofi-aventis Announces Second Quarter 2009 Results 8Sanofi-aventis Announces Second Quarter 2009 Results 9Sanofi-aventis Announces Second Quarter 2009 Results 10Sanofi-aventis Announces Second Quarter 2009 Results 11Sanofi-aventis Announces Second Quarter 2009 Results 12Sanofi-aventis Announces Second Quarter 2009 Results 13Sanofi-aventis Announces Second Quarter 2009 Results 14Sanofi-aventis Announces Second Quarter 2009 Results 15Sanofi-aventis Announces Second Quarter 2009 Results 16Sanofi-aventis Announces Second Quarter 2009 Results 17Sanofi-aventis Announces Second Quarter 2009 Results 18Sanofi-aventis Announces Second Quarter 2009 Results 19Sanofi-aventis Announces Second Quarter 2009 Results 20Sanofi-aventis Announces Second Quarter 2009 Results 21Sanofi-aventis Announces Second Quarter 2009 Results 22Sanofi-aventis Announces Second Quarter 2009 Results 23Sanofi-aventis Announces Second Quarter 2009 Results 24Sanofi-aventis Announces Second Quarter 2009 Results 25Sanofi-aventis Announces Second Quarter 2009 Results 26Sanofi-aventis Announces Second Quarter 2009 Results 27iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies 2
    (Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
    (Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
    (Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
    Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
    ... Apricots are important to Turkey, the country where more ... the world. Looking to unlock the mystery of apricots, ... genetic relationship between apricot varieties. New research from a ... genetic link between Turkish and Hungarian apricot cultivars, yielding ...
    ... a recent issue of HortTechnology , Purdue University researchers ... study of the effects of a technique called "bulb dipping" ... applied as sprays or media drenches, bulb crops can be ... were designed to determine if dipping Easter lily bulbs in ...
    ... the XXI century. Recent data point to more than a ... 300 million are clinically obese. What is more, the rates ... 155 million children and adolescents being overweight, of which 40 ... what point corporal morphology was influenced by genetics, on the ...
    Cached Biology News:Genetic relationship between Hungarian and Turkish apricots confirmed 2Bulb dipping controls Easter lily growth 2The amount of adipose tissue should be taken into account in the fight against obesity 2The amount of adipose tissue should be taken into account in the fight against obesity 3
    ... BIOLASE Core Kit contains all ... polymerase assays on a wide ... addition to dNTPs, the Core ... widely used BIOLASE DNA polymerase, ...
    UGT1A7 (E-15)...
    Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
    ... to the third cytoplasmic loop of human ... KLH. The immunizing peptide has 79% homology ... Physical form: Solution in phosphate buffered saline, ... Titertest method: IHC (p). Titertest values: ...
    Biology Products: